UPDATE : Friday, December 6, 2019
상단여백
SK Biopharm set to ensure superiority in antiepileptic drug by Jeong Sae-im 2019-12-04 16:18
Samyang Biopharm’s US subsidiary to work on new immunotherapy by Jeong Sae-im 2019-12-03 15:37
Alteogen inks licensing-out deal for SC injection formulation technology by Jeong Sae-im 2019-12-02 15:25
Daewoong challenges gastric acid blocker K-Cab with Fexuprazan by Jeong Sae-im 2019-11-29 15:23
New Parkinson’s drug Ongentys lands on Korea by Jeong Sae-im 2019-11-28 14:52
라인
Kolon Life Science’s research head arrested for false Invossa data by Jeong Sae-im 2019-11-28 11:18
SK Chemicals wins FDA nod for patch-type Alzheimer’s drug by Jeong Sae-im 2019-11-27 18:24
Roche Diagnostics challenges IBM Watson with differentiated strategy in tailor-made treatment market by Jeong Sae-im 2019-11-21 15:48
Oncologists vow to fight cancer through precision medicine by Jeong Sae-im 2019-11-21 14:28
Vivozon’s acquisition of Lumimicro may aim at backdoor listing by Jeong Sae-im 2019-11-20 14:44
라인
PharmAbcine registers 1st patient for phase-2 trial on olinvacimab by Jeong Sae-im 2019-11-19 17:18
‘New law needed to curb rising chronic kidney disease’ by Jeong Sae-im 2019-11-19 11:45
‘Udenafil improved exercise in single ventricle heart disease’ by Jeong Sae-im 2019-11-18 14:48
Prosecutors raid drugmakers, distributors for suspected bid-rigging by Jeong Sae-im 2019-11-14 15:27
How can Korean drugmakers enter Europe successfully? by Jeong Sae-im 2019-11-13 15:22
라인
Samsung Bioepis expects ₩1 trillion biosimilar sales this year by Jeong Sae-im 2019-11-13 15:21
[News Focus] ‘FDA could allow resumption of Invossa trial’ by Jeong Sae-im 2019-11-12 15:48
Eunpyeong St. Mary’s Hospital adopts AI nursing documentation by Jeong Sae-im 2019-11-12 15:47
Genexine’s new immunotherapy shows stability even in high dose by Jeong Sae-im 2019-11-11 13:36
‘Cancer patients suffered side effects after taking anthelmintic drug’ by Jeong Sae-im 2019-11-08 13:30
여백
여백
여백
Back to Top